Lirentelimab
- Generic Name
- Lirentelimab
- Drug Type
- Biotech
- CAS Number
- 2283348-97-8
- Unique Ingredient Identifier
- SWS48LJU3T
- Background
Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Allakos Halts AK006 Development for Chronic Hives After Phase 1 Failure, Announces Restructuring
• Allakos' AK006 failed to demonstrate therapeutic efficacy in a Phase 1 trial for chronic spontaneous urticaria (CSU), leading to the discontinuation of its development.
• The company will reduce its workforce by 75% and explore strategic alternatives following the unsuccessful trial results.
• The Phase 1 trial enrolled 34 patients with moderate-to-severe CSU, but AK006 did not show significant improvement compared to placebo.
• Allakos anticipates restructuring costs of $34 million to $38 million and expects to have $35 million to $40 million in cash reserves by mid-2025.
FDA Approves DUPIXENT for Pediatric Eosinophilic Esophagitis, Expanding Treatment Options
The FDA has granted approval for DUPIXENT (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1-11 years weighing at least 15 kg. The approval follows successful Phase III EoE KIDS trial results showing superior histological remission rates compared to placebo. This development represents a significant advancement in treating pediatric EoE, a condition affecting approximately 1 in 2,000 people.
Urticaria Clinical Trial Pipeline Heats Up with Novel Therapies in Development
• The urticaria treatment landscape is evolving, with over 20 companies developing more than 25 novel therapies to address unmet patient needs.
• Regeneron and Sanofi's Dupixent demonstrated positive Phase III results for chronic spontaneous urticaria, showing promise for biologic-naive patients.
• Evommune initiated a Phase II trial of EVO756 for chronic inducible urticaria, while Celldex Therapeutics reported positive Phase II data for barzolvolimab in chronic spontaneous urticaria.
• Emerging therapies target various mechanisms, including IgE, mast cells, and kinases, offering diverse approaches to urticaria management.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath